FDA approves Eisai's Aciphex Sprinkle for pediatric GERD

03/27/2013 | Zenopa.com (U.K.) · Drug Store News

The FDA has approved the use of Eisai's Aciphex Sprinkle delayed-release capsules, or rabeprazole sodium, for up to 12 weeks in children ages 1 to 11 with gastroesophageal reflux disease. The approval was based on results of a multicenter trial in which 81% of Aciphex-treated pediatric patients responded during the 12-week treatment period.

View Full Article in:

Zenopa.com (U.K.) · Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA